Singapore markets close in 4 hours 25 minutes

ABBV Feb 2023 160.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.0500+0.0500 (+2.50%)
As of 02:40PM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?

    AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.

  • Motley Fool

    Bear Market Bargains: 3 Dividend Stocks to Buy Now

    All three of these stocks are attractively valued even though they're beating the market this year.

  • Motley Fool

    Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

    With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.